Lifecore Biomedical, Inc. (NASDAQ:LFCR) Expected to Post FY2025 Earnings of ($1.03) Per Share

Lifecore Biomedical, Inc. (NASDAQ:LFCR) – Stock analysts at Barrington Research issued their FY2025 earnings per share (EPS) estimates for shares of Lifecore Biomedical in a research report issued on Wednesday, August 28th. Barrington Research analyst M. Petusky expects that the company will earn ($1.03) per share for the year. Barrington Research currently has a “Market Perform” rating on the stock. The consensus estimate for Lifecore Biomedical’s current full-year earnings is ($0.73) per share.

Lifecore Biomedical Stock Up 14.7 %

Shares of NASDAQ:LFCR opened at $4.38 on Monday. The stock has a 50-day simple moving average of $5.32 and a 200-day simple moving average of $6.03. The stock has a market capitalization of $132.81 million, a P/E ratio of -1.31 and a beta of 0.97. Lifecore Biomedical has a 1 year low of $3.68 and a 1 year high of $9.09. The company has a debt-to-equity ratio of 12.90, a quick ratio of 0.99 and a current ratio of 2.08.

Lifecore Biomedical (NASDAQ:LFCR) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.05) EPS for the quarter. The firm had revenue of $35.70 million for the quarter. Lifecore Biomedical had a negative return on equity of 515.12% and a net margin of 9.37%.

Hedge Funds Weigh In On Lifecore Biomedical

A number of hedge funds have recently made changes to their positions in the business. Legion Partners Asset Management LLC boosted its position in Lifecore Biomedical by 0.6% during the 2nd quarter. Legion Partners Asset Management LLC now owns 2,968,409 shares of the company’s stock worth $15,228,000 after purchasing an additional 18,182 shares during the period. Marshall Wace LLP raised its position in Lifecore Biomedical by 87.3% in the second quarter. Marshall Wace LLP now owns 300,120 shares of the company’s stock valued at $1,540,000 after purchasing an additional 139,887 shares during the period. DCF Advisers LLC lifted its stake in shares of Lifecore Biomedical by 2.1% during the second quarter. DCF Advisers LLC now owns 290,684 shares of the company’s stock worth $1,491,000 after purchasing an additional 6,000 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Lifecore Biomedical in the second quarter worth about $56,000. Finally, Allegheny Financial Group LTD acquired a new stake in shares of Lifecore Biomedical in the second quarter valued at about $52,000. Hedge funds and other institutional investors own 83.36% of the company’s stock.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.